Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jul 24;124(4):468-9.
doi: 10.1182/blood-2014-06-578625.

Carfilzomib: a new opportunity for WM patients

Enrica Morra  1
Affiliations
Comment

Carfilzomib: a new opportunity for WM patients

Enrica Morra. Blood. .

Abstract

In this issue of Blood, Treon et al report the results of carfilzomib combined with rituximab and dexamethasone as a new effective and neuropathy-sparing treatment for patients with Waldenström macroglobulinemia (WM) requiring proteasome inhibitor-based therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Comment on

References

    1. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood. 2014;124(4):503–510. - PubMed
    1. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Bortezomib in Waldenström’s Macroglobulinemia. Haematologica. 2005;90:1655–1658. - PubMed
    1. Chen CI, Kouroukis CT, White D, et al. National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–1575. - PubMed
    1. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830–3835. - PMC - PubMed
    1. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276–3282. - PubMed

MeSH terms